Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
838853-48-8
Molecular formula
C59H110N6NaO20P
Molecular weight
1277.5 g/mol
Drug class
Liposomal immunostimulantNOD2 agonist and macrophage activator
Mechanism of action
Mifamurtide (muramyl tripeptide phosphatidyl ethanolamine, MTP-PE) is a synthetic muramyl dipeptide derivative delivered in a liposomal formulation designed for uptake by monocytes and macrophages. It activates intracellular NOD2 receptors, stimulating cytokine release and macrophage-mediated antitumour activity. The exact contribution of each immune mechanism to clinical benefit is not fully defined.
Indications / reported uses
Treatment of children, adolescents and young adults with high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in combination with postoperative multi-agent chemotherapy.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mifamurtide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mifamurtide Permitted Daily Exposure (PDE) report (the Mifamurtide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mifamurtide Occupational Exposure Limit (OEL) report (the Mifamurtide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.